← Leaderboards
Teodora Nicola
Resbiotic, Inc.
$2,290,381
Attributed
$2,290,381
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $999.4K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$2,290,381 · 1
By mechanism
R44$2,290,381 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Acute”
- Taleen Hanania · Psychogenics, Inc.$9,482,040
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Christopher J. Lindsell · Vanderbilt University Medical Center$8,536,327
- Michael E. Roth · Public Health Institute$8,201,777
- Jacob Sutton Coverstone · Neurovations$6,882,205
- Agustin G Yip · Albert Einstein College Of Medicine$6,090,308
Research focus
AcuteAdrenal Cortex HormonesAffectAirway RemodelingAlternative TreatmentAmericanAnimalsAnti-Inflammatory AgentsBacteriaBiological Response Modifier TherapyBiologyBronchial EpitheliumBronchodilator AgentsCause Of DeathCell Culture TechniquesCell ModelCellsCessation Of LifeChemical StabilityChemokineChronicChronic Inflammatory Lung DiseaseChronic Lung DiseaseAcetylation
Grant awards (4)
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD$992,385
R44 · FY2025 · HL · contact PI
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD$999,425
R44 · FY2024 · HL · contact PI
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD$295,274
R44 · FY2023 · HL · contact PI
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD$3,297
R44 · FY2023 · HL · contact PI